KMC Speciality (524520)

Fast Grower

FairStock Score: 46/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Current Price₹81.32
Market Cap₹1,333.88 Cr
P/E Ratio38.15
ROCE17.37%
ROE23.96%
Dividend Yield0%
Profit Growth82.82%
Debt/Equity
Sales Growth33.74%
52-Week Range₹65.01 — ₹97.6
SectorHealthcare Services
Book Value₹9.69

Strengths

Concerns

AI Analysis

Let me look at KMC Speciality the way I look at any business—through numbers, not noise. The company earns a return on equity of 23.96% and a ROCE of 17.37%, so it is converting capital into profits efficiently. Book value is only ₹9.69, yet the market pays ₹81.32, a price-to-book of 8.39; that is a rich price, but quality often demands a premium. Sales grew 33.74% and profits jumped 82.82%, and the Piotroski F-Score of 7/9 suggests the earnings quality is backed by solid fundamentals. On the surface, a P/E of 38.15 looks expensive, but the PEG ratio of 0.65 tells me the growth is doing a lot of the heavy lifting. I won't overpay for momentum; I need the growth to continue. The latest quarter shows sales of ₹82 crore and net profit of ₹14 crore, so the engine is still running. Still, I have reservations. There is no dividend—zero yield—so my return wholly depends on reinvestment and eventual valuation. Promoter holding is not disclosed in the data I have; I cannot judge whether the people running the shop have enough skin in the game. Debt-to-equity is also not available, leaving a gap in my safety check. FairStock Score of 43/100 is mixed; the market is paying for a wonderful business, but I must ask whether it is a wonderful price. If growth moderates, a high P/E leaves little margin of safety. I would keep it on my watch list, not my buy list, unless the price falls or earnings catch up with optimism.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer